

CLNR414

Advanced Topics in Clinical Research 2

View Online



[1]

M. Komorowski, L. A. Celi, O. Badawi, A. C. Gordon, and A. A. Faisal, 'The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care', *Nature Medicine*, vol. 24, no. 11, pp. 1716–1720, Nov. 2018, doi: 10.1038/s41591-018-0213-5.

[2]

D. McPherson et al., 'Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010', *BMJ Open*, vol. 3, no. 8, Aug. 2013, doi: 10.1136/bmjopen-2013-002586.

[3]

D. C. Norman, 'Fever in the Elderly', *Clinical Infectious Diseases*, vol. 31, no. 1, pp. 148–151, Jul. 2000, doi: 10.1086/313896.

[4]

'Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program* | Ovid', 2014.
<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003246&LSLINK=80&D=jbi>

[5]

L. Evans, 'A Closer Look at Sepsis-Associated Mortality', *JAMA Network Open*, vol. 2, no. 2, Feb. 2019, doi: 10.1001/jamanetworkopen.2018.7565.

[6]

D. De Backer and T. Dorman, 'Surviving Sepsis Guidelines', JAMA, vol. 317, no. 8, Feb. 2017, doi: 10.1001/jama.2017.0059.

[7]

M. Sund-Levander, C. Forsberg, and L. K. Wahren, 'Normal oral, rectal, tympanic and axillary body temperature in adult men and women: a systematic literature review', Scandinavian Journal of Caring Sciences, vol. 16, no. 2, pp. 122-128, Jun. 2002, doi: 10.1046/j.1471-6712.2002.00069.x.

[8]

C. Rhee et al., 'Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals', JAMA Network Open, vol. 2, no. 2, Feb. 2019, doi: 10.1001/jamanetworkopen.2018.7571.

[9]

M. Singer et al., 'The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)', JAMA, vol. 315, no. 8, Feb. 2016, doi: 10.1001/jama.2016.0287.

[10]

M. D. Howell and A. M. Davis, 'Management of Sepsis and Septic Shock', JAMA, vol. 317, no. 8, Feb. 2017, doi: 10.1001/jama.2017.0131.

[11]

C. W. Seymour et al., 'Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis', JAMA, vol. 321, no. 20, May 2019, doi: 10.1001/jama.2019.5791.

[12]

W. A. Knaus and R. D. Marks, 'New Phenotypes for Sepsis', JAMA, vol. 321, no. 20, May 2019, doi: 10.1001/jama.2019.5794.

[13]

S. Zhou et al., 'miRNAs in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges', *Acta Pharmacologica Sinica*, vol. 39, no. 7, pp. 1073–1084, Jul. 2018, doi: 10.1038/aps.2018.30.

[14]

'Circulation Research', [Online]. Available:
<https://www.ahajournals.org/doi/full/10.1161/01.RES.0000252802.25497.b7>

[15]

'Circulation Research', [Online]. Available:
<https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.116.309692>

[16]

G. Wick and C. Grundtman, Eds., *Inflammation and Atherosclerosis*. Vienna: Springer Vienna, 2012. doi: 10.1007/978-3-7091-0338-8.

[17]

P. C. Westman et al., 'Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction', *Journal of the American College of Cardiology*, vol. 67, no. 17, pp. 2050–2060, May 2016, doi: 10.1016/j.jacc.2016.01.073.

[18]

N. G. Frangogiannis, 'Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities', *Molecular Aspects of Medicine*, vol. 65, pp. 70–99, Feb. 2019, doi: 10.1016/j.mam.2018.07.001.

[19]

'Circulation Research', [Online]. Available:
<https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.116.308537>

[20]

'Arteriosclerosis, Thrombosis, and Vascular Biology', [Online]. Available: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.119.311996?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

[21]

A. Hafiane and S. S. Daskalopoulou, 'Extracellular vesicles characteristics and emerging roles in atherosclerotic cardiovascular disease', *Metabolism*, vol. 85, pp. 213–222, Aug. 2018, doi: 10.1016/j.metabol.2018.04.008.

[22]

'Circulation Research', [Online]. Available: <https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.117.312465>

[23]

S. Huang and N. G. Frangogiannis, 'Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges', *British Journal of Pharmacology*, vol. 175, no. 9, pp. 1377–1400, May 2018, doi: 10.1111/bph.14155.

[24]

'Arteriosclerosis, Thrombosis, and Vascular Biology', [Online]. Available: <https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.110.207480>